Further Development of XenoPort (XNPT) '829 is Unwarranted, Cowen Says

Cowen analyst Eric Schmidt reiterated an Market Perform rating on XenoPort (NASDAQ: XNPT) noting the XP23829 was active in the latest data but "unimpressive."

Schmidt commented, "XenoPort released Phase II data on '829 (a prodrug of monomethyl fumarate) for the treatment of moderate to severe psoriasis. While the drug demonstrated clear activity, we think neither its efficacy or safety profile appear compelling or differentiated. We do not believe further development of '829 is warranted."

For an analyst ratings summary and ratings history on XenoPort click here. For more ratings news on XenoPort click here.

Shares of XenoPort closed at $6.73 yesterday.

You May Also Be Interested In

• TD Cowen Resumes EQT Corp. (EQT) at Hold
• Piper Sandler Downgrades Southwestern Energy (SWN) to Neutral
• Prysmian SpA (PRY:IM) (PRYMY) PT Raised to EUR53 at HSBC